Journal
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
Volume 25, Issue 7, Pages 1223-1232Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s10147-020-01684-z
Keywords
Gastric cancer; Prognostic factor; Tumor marker; RECIST
Categories
Ask authors/readers for more resources
After failure of first-line chemotherapy with fluoropyrimidines and platinum compounds for advanced gastric cancer, second-line chemotherapy with ramucirumab plus paclitaxel, which elicits a durable response, and third-line or later chemotherapy with nivolumab have been shown to lead to a more favorable prognosis in advanced gastric cancer patients. As new and more effective drugs are now available, sequential chemotherapy would contribute to prolonged survival. From this point of view, the patient's disease course should be frequently monitored in order to adapt treatment regimens. This review summarizes the points to note in regard to radiological assessment, and discusses the integration of prognostic factors, tumor markers, and clinical symptoms that need to be taken into account to change treatment at an appropriate timing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available